UCBMEX:UCBN 85 Days Payable is 351.17 as of Dec. 2025, which is 191% above its 10-year median of 120.66. GuruFocus rates MEX:UCBN with a GF Score™ of 85/100 and a GF Value™ of MXN1,417.06. The stock has 2 warning signs investors should review. Among 707 Biotechnology companies, UCB ranks better than 70.3% on this metric.
UCB's average Accounts Payable for the
six
months ended in Dec. 2025 was MXN43,328 Mil. UCB's Cost of Goods Sold for the
six
months ended in Dec. 2025 was MXN22,518 Mil.
Hence, UCB's Days Payable for the
six
months ended in Dec. 2025 was 351.17.
The historical rank and industry rank for UCB's Days Payable or its related term are showing as below:
MEX:UCBN'
s Days Payable Range Over the Past 10 Years
Min: 75.76 Med: 120.66 Max: 291.27
Current: 291.27
During the past 13 years, UCB's highest Days Payable was 291.27. The lowest was 75.76. And the median was 120.66.
MEX:UCBN's Days Payable is ranked better than 70.3% of 707
companies
in the Biotechnology industry
Industry Median: 113.76
vs MEX:UCBN: 291.27
UCB's Days Payable
increased
from Dec. 2024 (296.82) to Dec. 2025 (351.17).
It may suggest that UCBdelayed paying its suppliers.
UCB Days Payable Related Terms
UCB Days Payable Historical Data
* Premium members only.
The historical data trend for UCB's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:UCBN vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, UCB's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
UCB Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, UCB's Days Payable distribution charts can be found below:
* The bar in red indicates where UCB's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
UCB's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UCB (MEX:UCBN) has a Days Payable of 351.17 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on UCB and its competitors. This is 191% above median its historical median of 120.66. Over the past decade, UCB's Days Payable has ranged from 75.76 to 291.27. According to the industry distribution chart, UCB ranks #210 out of 707 companies in the Biotechnology industry, placing it in the top 29.7%.
Is UCB's Days Payable too high?
UCB's current Days Payable of 351.17 is 191% above median its 10-year median of 120.66. Over the past 10 years, this metric has ranged from a low of 75.76 to a high of 291.27. The Biotechnology industry median Days Payable is 113.76. UCB's value of 351.17 is 208.7% above this industry median. Based on the distribution chart, UCB ranks #210 out of 707 companies in the Biotechnology industry, which is above the industry midpoint. Overall, UCB has a GF Score™ of 85/100, reflecting its overall financial health beyond just this single metric.
How does UCB's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, UCB ranks #210 out of 707 companies for Days Payable. This puts UCB in the upper half of its industry. The industry median Days Payable is 113.76. UCB's value of 351.17 is 208.7% above this benchmark. Historically, UCB's own Days Payable has ranged from 75.76 to 291.27 over the past decade. While the company's 10-year median is 120.66 vs. the industry median of 113.76, UCB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.76, based on 707 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. UCB's current Days Payable of 351.17 is 208.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on UCB and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. UCB's current Days Payable is 351.17, which is 191% above median its own 10-year median of 120.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UCB stock overvalued right now?
UCB (MEX:UCBN) has a current Days Payable of 351.17. The stock's GF Value™ is MXN1,417.06, compared to a current price of MXN1,692.27 — trading 19.4% above its estimated fair value. The current Days Payable is 351.17, which is 191% above median its 10-year median of 120.66 and 208.7% above the Biotechnology industry median of 113.76. UCB's overall GF Score™ is 85/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For UCB (MEX:UCBN), the current Days Payable is 351.17 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is UCB (MEX:UCBN) Overvalued in 2026?
Based on GuruFocus' analysis, UCB stock appears to be overvalued.
The current stock price of MXN1,692.27 is trading 19.4% above its estimated GF Value™ of MXN1,417.06.
Key valuation signals for MEX:UCBN:
Days Payable: 351.17 (191% above median its 10-year median of 120.66)
GF Value™: MXN1,417.06 vs. price of MXN1,692.27 (19.4% above fair value)
Industry Position: 208.7% above the Biotechnology median (#210 of 707)
No single metric tells the full story. See the MEX:UCBN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome), and Kygevvi (rare mitochondrial disease).
85GF Score
Get the complete analysis for MEX:UCBN
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:UCBN has been successfully added to your 
